Brainomix and Boehringer Ingelheim Partner to Enhance Diagnosis and Treatment of Fibrosing Lung Disease

Brainomix, a leader in AI imaging solutions, has entered into a strategic partnership with Boehringer Ingelheim, a German pharmaceutical company, to improve care for patients with fibrosing lung disease in the US.

This collaboration aims to leverage Brainomix’s e-Lung imaging software to enhance the identification and access to treatment for individuals with progressive pulmonary fibrosis.

The project will utilize Brainomix 360 e-Lung on routine CT scans to speed up diagnosis and improve treatment access for fibrosing lung disease, a chronic and life-limiting condition. Pulmonary fibrosis can drastically shorten patients' lifespans, often limiting them to as few as five years post-diagnosis if untreated. Currently, diagnosis can take up to two years, delaying critical treatment initiation.

Image: Brainomix 360 e-Lung

Brainomix’s FDA-cleared e-Lung software will be deployed across leading US pulmonology centers and their networks of referring sites. The data generated will validate the software's effectiveness, showcasing the potential of digital technology to optimize care pathways and improve patient outcomes. This initiative aligns with the shared vision of Brainomix and Boehringer Ingelheim to enhance the management of fibrosing lung disease.

Dr Michalis Papadakis, CEO and Co-Founder of Brainomix said:

“There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease. The patient pathway for people with fibrosing lung disease is currently fragmented and, it can take many years for a patient to be diagnosed.

Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim, noted the importance of early and confident detection of disease progression. He believes that Brainomix 360 e-Lung can revolutionize diagnostics and enable earlier treatment decisions, ultimately improving patient outcomes and quality of life.

See also: First-of-its-kind AI-based Diagnostics Solutions Approved in Europe

Brainomix 360 e-Lung received FDA clearance in May 2024. The same month, Brainomix presented new studies at the American Thoracic Society (ATS) Conference in San Diego, highlighting the prognostic value of its lung imaging biomarkers. These studies reflect the company's expanding partnerships and collaborations in the lung disease research community.

Topics: HealthTech